Compare · CON vs ILMN
CON vs ILMN
Side-by-side comparison of Concentra Group Holdings Parent Inc. (CON) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CON and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $40.46B, about 8.1x CON ($4.99B).
- ILMN has been more active in the news (8 items in the past 4 weeks vs 2 for CON).
- ILMN has more recent analyst coverage (25 ratings vs 14 for CON).
- Company
- Concentra Group Holdings Parent Inc.
- Illumina Inc.
- Price
- -
- -
- Market cap
- $4.99B
- $40.46B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2024
- 2000
- News (4w)
- 2
- 8
- Recent ratings
- 14
- 25
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest CON
- Jefferies initiated coverage on Concentra with a new price target
- Concentra to Announce Third Quarter 2026 Results on Thursday, November 5, 2026
- Concentra Expands Florida Footprint with New Daytona Beach Medical Center
- Concentra Group Holdings Parent Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Concentra Appoints Tanner Newton Chief Financial Officer
- Amendment: SEC Form SCHEDULE 13D/A filed by Concentra Group Holdings Parent Inc.
- Amendment: Director Ortenzio Robert A returned $34,650,000 worth of shares to the company (1,000,000 units at $34.65), decreasing direct ownership by 14% to 4,663,794 units (SEC Form 4)
- Concentra Group Holdings Parent Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Director Ortenzio Robert A returned $34,680,000 worth of shares to the company (1,000,000 units at $34.68), decreasing direct ownership by 14% to 4,763,794 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by Concentra Group Holdings Parent Inc.
Latest ILMN
- Illumina launches BioInsight Platform, its first unified software environment to help accelerate genomic and multiomic breakthroughs
- SEC Form 8-K filed by Illumina Inc.
- Illumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026
- Illumina releases SpliceAI2 to help advance rare disease research
- SEC Form 4 filed by Illumina Inc.
- SEC Form SCHEDULE 13G filed by Illumina Inc.
- Director Meister Keith A. was granted 107 shares, increasing direct ownership by 2% to 6,887 units (SEC Form 4)
- Director Ullem Scott B. was granted 113 shares, increasing direct ownership by 1% to 11,143 units (SEC Form 4)
- Chief Legal Officer Coletti Julie Ann was granted 18,763 shares (SEC Form 4)
- SVP, Chief Technology Officer Barnard Steven covered exercise/tax liability with 408 shares, decreasing direct ownership by 0.99% to 40,927 units (SEC Form 4)